|
Jan 1, 2012
By:
Mason Tenaglia
Mason Tenaglia offers empirical defense of coupons and copay offset programs.
|
May 1, 2011
By:
Mason Tenaglia
The pharmaceutical industry needs to use new and better data to accurately measure how much it is willing to invest in avoiding plan control
|
|
Jan 1, 2010
By:
Mason Tenaglia
Designing and deploying company copay offset programs without devaluing the brand.
|
|
Companies that will be forced to cut back on sales and marketing spending must focus on value, not volume. Here's how to reduce your spend where it matters the least.
Sep 1, 2005
By:
Mason Tenaglia, Patrick Angelastro
When rebate strategies are coupled with sales force and DTC spending, it results in "margin-negative" business—that is, sales that bring in less than the marginal cost of selling, promoting, and manufacturing the drug.
|
What big pharma companies can learn from the evolution of the infant formula business
Sep 1, 2004
By:
Mason Tenaglia
The dynamic that drove the profits out of infant formula is about to be repeated—this time in pharma.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
